Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 30;24(18):4416–4428. doi: 10.1158/1078-0432.CCR-17-3649

Figure 5. Mutation load and tumor recognition are not affected by exposure to anti-CTLA4.

Figure 5

(A–B) Non-synonymous mutation load obtained from whole genome sequencing (WES) from tumor utilized for TIL propagation of treated patient. The graphs compare the mutation load from responders and non-responders (A) and from stratifying these 2 categories: CR and PR for responders and SD and PD for non-responders (B). (C) Pre-REP TIL from treated patients were co-cultured with autologous tumor targets and assessed for IFNg production by ELISA. The percentage of patients displaying tumor recognition (>200 pg/mL) is shown in black. (D) The average of IFNg secreted by the TIL lines in both group of patients capable of autologous tumor recognition shown in (C). (E) Non-synonymous mutation load comparing checkpoint naive tumors vs anti-CTLA4 exposed tumors. (F) Pre-REP TIL (regardless of patient receiving TIL therapy) were co-cultured and assessed for IFNg production as mentioned in (C). (G) The average of IFNg secreted by the TIL lines in both group of patients capable of autologous tumor shown in (F).